Abstract
In recent years, the need for a non-invasive diagnostic tool that would help to discriminate 1 between organic (e.g.: infections, food allergy-related disorders, inflammatory bowel 2 diseases) and functional gastrointestinal disorders (e.g.: Toddler diarrhea, irritable bowel 3 syndrome, infant colic) directed research towards potential immunological markers. A great 4 number of non-invasive bio-markers have been proposed, including eosinophilic cationic 5 protein, elastase, esterase, myeloperoxidase, lysozyme, lactoferrin, and calprotectin (Limburg 6 PJ, Ahlquist DA, Sandborn WJl, 2000; Roseth AG, 2003; Costa F et al, 2003) . Compared to 7 other biomarkers, calprotectin (also called MRP8/14, calgranulin A/B , cystic fibrosis antigen 8 or S100 A8/A9) may offer advantages based on its biological characteristics. Calprotectin is a 9 36.5-kDa, calcium and zinc binding polypeptide which constitutes about 60% of soluble 10 cytosol proteins in human neutrophils (Poullis A et al, 2003) . It is also found in monocytes, 11 keratinocytes, muscle tissue and infiltrating tissue macrophages (Poullis A et al, 2003) . When 12 bound to calcium it becomes resistant to proteolysis and colonic bacterial degradation. This 13 make is stable for up to 1 week at room temperature and facilitate its determination in feces 14 (Costa F et al, 2003; Aadland E, Fagerhol MK, 2002) . Calprotectin is involved in the (Campeotto F et al 2004) . Despite this evidence, the measurement of calprotectin in the 28 serum has been proposed to identify neonates with necrotizing enterocolitis (Terrin G et al, 29 2012). Recent studies have shown higher fecal calprotectin levels in infants with irritable 30 bowel syndrome (IBS) and colics, compared with healthy controls (Shulman RJ et al 2008;  31 Rhoads JM et al, 2009 ). Additionally a correlation was found between fecal calprotectin 32 concentration and IBS clinical presentation severity (Rhoads JM et al, 2009 
